‘Personalised medicine’ approach could improve quality of life for bowel cancer patients
Monday 19 March 2018
A research study published today in the Journal of Pathology has shown how a ‘personalised medicine’ approach could improve the prognosis and quality of life of bowel cancer patients.
The research, led by Queen’s University Belfast, demonstrates for the first time how analysing biopsy samples from clinical trials can help clinicians better understand and treat the disease and improve outcomes in ongoing clinical trials.
The study is part of the Stratification in Colorectal Cancer (S:CORT) consortium led by Professor Tim Maughan from the University of Oxford.
Deborah Alsina MBE, Chief Executive of Bowel Cancer UK and Beating Bowel Cancer which is a partner in S:CORT, says: “We are delighted to be associated with this research. Our recent Critical Research Gaps in Colorectal Cancer Initiative highlighted the need for better research collaboration. This is an excellent example of the best UK science and clinical care in bowel cancer working together to develop innovative approaches to save more lives.”